

<b>INFORMATION DISCLOSURE</b>		ATTY. DOCKET NO.	SERIAL NO.
<b>CITATION</b>		620-439	10/579,230
APPLICANT			
VELDMAN et al.			
(Use several sheets if necessary)		FILING DATE	GROUP
		May 12, 2006	unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
1	4,416,872	11/1983	Alving			
2	5,013,556	05/1991	Woodle			
3	5,213,804	05/1993	Martin			
4	5,395,619	03/1995	Zalipsky			
5	5,527,528	06/1996	Allen			
6	5,800,833	09/1998	Hope			
7	2002/0119990	08/2002	Madden			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
8	WO 88/01171	02/1988	WIPO				
9	WO 99/41266	08/1999	WIPO				
10	WO 02/02077	01/2002	WIPO				
11	EP 0 896 816	02/1999	Europe				
12	JP 8-034746	02/1996	Japan			X	

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

13	Abraham SA, et al, 2002, "Formation of transition metal-doxorubicin complexes inside liposomes," <u>Biochim. Biophys. Acta.</u> , Vol. 1565(1), pp. 41-54.
14	Bai J, et al, 1997, "Measurement of spontaneous transfer and transbilayer movement of BODIPY-labeled lipids in lipid vesicles," <u>Biochemistry</u> , Vol. 36, pp. 8840-8848.
15	Bligh EJ, et al, 1959, "A rapid method of total lipid extraction and purification," <u>Can. J. Biochem. Physiol.</u> , Vol. 37, pp. 911-917.
16	Carmichael J, et al, 1987, "Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing," <u>Cancer Res.</u> , Vol. 47, pp. 936-942.
17	Cheung BC, et al, 1998, "Loading of doxorubicin into liposomes by forming Mn <sup>2+</sup> -drug complexes," <u>Biochim. Biophys. Acta.</u> , Vol. 1414(1-2), pp. 205-216.
18	Druckmann S, et al, 1989, "Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies," <u>Biochim. Biophys. Acta</u> , Vol. 980, pp. 381-384.
19	Everts M, et al, 2003, "In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium," <u>Pharm. Res.</u> , Vol. 20, pp. 64-72.
20	Gabizon A, 2001, "Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy," <u>Cancer Inv.</u> , Vol. 19, pp. 424-436.

Examiner	/Michael Henry/	Date Considered	01/02/2010
----------	-----------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
<b>CITATION</b>		620-439	10/579,230
		APPLICANT	
		VELDMAN et al.	
(Use several sheets if necessary)		FILING DATE	GROUP
		May 12, 2006	unknown

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

21	Gabizon A, et al, 1996, "Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines," <u>J. Drug Target</u> , Vol. 3, pp. 391-398.
22	Ghidoni R, et al, 1999, "Use of sphingolipid analogs: benefits and risks," <u>Biochim. Biophys. Acta</u> , Vol. 1439, pp. 17-39.
23	Haran G, et al Y, 1993, "Transmembrane ammonium sulphate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases," <u>Biochim. Biophys. Acta</u> , Vol. 1151, pp. 201-215.
24	Harasym TO, et al, 1997, "Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/ cholesterol liposomes," <u>Cancer Chemother. Pharmacol.</u> , Vol. 40, pp. 309-317.
25	Heijn M, et al, 1999, "Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor," <u>Cancer Res.</u> , Vol. 59, pp. 4458-4463.
26	Horowitz AT, et al, 1992, "In vitro cytotoxicity of liposome-encapsulated doxubicin: dependence on liposome composition and drug release," <u>Biochim. Biophys. Acta</u> , Vol. 1109, pp. 203-209.
27	Jeckel D, et al, 1993, "Truncated ceramide analogs as probes for sphingolipid biosynthesis and transport," <u>Adv. Lipid Res.</u> , Vol. 26, pp. 143-160.
28	Koning GA, et al, 1999, "Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells," <u>Br. J. Cancer</u> , Vol. 80, pp. 1718-1725.
29	Koning GA, et al, 2003, "Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer Cells. An in vitro comparison," <u>Pharm. Res.</u> , Vol. 20, pp. 1249-1257.
30	Koning, G.A., et al, 2003, "Short-chain liposomal sphingolipids potentiate in vitro doxorubicin cytotoxicity by enhancing its cellular influx," Conference Abstract for Liposome Advances: Progress in Drug and Vaccine Delivery, 15-19 December 2003, London, UK.
31	asic DD, et al, 1995, "Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery," <u>Biochim. Biophys. Acta</u> , Vol. 1239(2), pp. 145-156.
32	Lothstein L, et al, 2001, "Anthracyclin drug targeting: cytoplasmic versus nuclear - a fork in the road," <u>Drug Res. Updates</u> , Vol. 4, pp. 169-177.
33	Mabrey, S., et al, 1978, "High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines", <u>Biochem.</u> , Vol. 17, pp. 2464-2468.
34	Martin, F.J., 1990, "Pharmaceutical Manufacturing of Liposomes", <u>Specialized Drug Delivery Systems - Manufacturing and Production Technology</u> , pp. 267-316.

\*Examiner /Michael Henry/ Date Considered 01/02/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.C.H./

<b>INFORMATION DISCLOSURE</b>		ATTY. DOCKET NO.	SERIAL NO.
<b>CITATION</b>		620-439	10/579,230
		APPLICANT	
		VELDMAN et al.	
(Use several sheets if necessary)		FILING DATE	GROUP
		May 12, 2006	unknown

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

35	Mayer, L.D., et al, 1986, "Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient", <u>Biochim. Biophys. Acta</u> , Vol. 857, pp. 123-126.
36	Mayer, L.D., et al., 1989, "Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in Mice", <u>Cancer Res.</u> , Vol. 49, pp. 5922-5930.
37	Olson, F., et al, 1979, "Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes", <u>Biochim. Biophys. Acta</u> , Vol. 557, pp. 9-23.
38	Pan, XQ, et al, 2003, "Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model," <u>Pharm. Res.</u> , Vol. 20, pp. 417-422.
39	Park, JW, et al, 2002, "Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery," <u>Clin. Cancer Res.</u> , Vol. 8, pp. 1172-1181.
40	Robert J, et al, 1993, "Pharmacokinetics and metabolism of anthracyclines," in <u>Cancer Surveys</u> , Vol. 17, pp. 219-252.
41	Rouser G, et al, 1970, "Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots," <u>Lipids</u> , Vol. 5, pp. 494-496.
42	Sillence, D.J., et al., 2000, "Assay for the transbilayer distribution of glycolipids: selective oxidation of glucosylceramide to glucuronylceramide by TEMPO nitroxyl radicals", <u>Journal of Lipid Research</u> , Vol. 41, pp. 1252-1260.
43	Smith PK, et al, 1985, "Measurement of protein using bicinchoninic acid," <u>Anal. Chem.</u> , Vol. 150, pp. 76-85.
44	Speth PA, et al, 1988, "In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells," <u>Eur. J. Cancer Clin. Oncol.</u> , Vol. 24, pp. 667-674.
45	Storm G, et al, 1985, "The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation", <u>Biochim. Biophys. Acta</u> , Vol. 818, pp. 343-351.
46	Szoka, F., Jr., et al, 1980, "Comparative properties and methods of preparation of lipid vesicles (liposomes)", <u>Ann. Rev. Biophys. Biogen.</u> , Vol. 9, p. 457.
47	Tardi PG, et al, 1996, "Liposomal doxorubicin," <u>J. Drug Target</u> , Vol. 4, pp. 129-140.
48	Tsong, T.Y., 1975, "Effect of phase transition on the kinetics of dye transport in phospholipid bilayer structures", <u>Biochem.</u> , Vol. 14, pp. 5409-5414; pp. 5415-5417.
49	Tubaro, E., et al, 1995, "Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models," <u>European Journal of Pharmacology</u> , Vol. 294, pp. 555-563.
50	Uster PS, et al, 1996, "Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time," <u>FEBS Lett.</u> , Vol. 386, pp. 243-246.

*Examiner	/Michael Henry/	Date Considered	01/02/2010
-----------	-----------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.C.H./

1121812

\*Examiner /Michael Henry/ Date Considered 01/02/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.G.H./